Streetbeat News

Analyst Ratings

VYNE

HC Wainwright & Co. has reiterated its Buy rating for VYNE Therapeutics, maintaining a price target of $5.75.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:33 pm

BAM

Goldman Sachs analyst Alexander Blostein has maintained a Buy rating on Brookfield Asset Management (NYSE:BAM) and increased the price target from $41 to $47.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:32 pm

SABS

Oppenheimer analyst Leland Gershell has reiterated an Outperform rating for SAB Biotherapeutics (NASDAQ:SABS) and maintained a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:28 pm

LRCX

UBS analyst Timothy Arcuri maintains a Buy rating on Lam Research (NASDAQ:LRCX) but lowers the price target from $1250 to $1150.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:27 pm

KLAC

UBS analyst Timothy Arcuri has maintained a Neutral rating on KLA (NASDAQ:KLAC) but has lowered the price target from $900 to $765.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:25 pm

DBI

UBS analyst Jay Sole maintains a Neutral rating on Designer Brands (NYSE:DBI) but lowers the price target from $9 to $5.5.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:23 pm

AMAT

UBS analyst Timothy Arcuri maintains a Neutral rating on Applied Materials (NASDAQ:AMAT) and lowers the price target from $220 to $210.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:22 pm

UDR

UBS analyst Michael Goldsmith has maintained a Buy rating on UDR and raised the price target from $48 to $52.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:21 pm

FULC

Cantor Fitzgerald has downgraded Fulcrum Therapeutics from Overweight to Neutral, indicating a change in the analyst's outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:19 pm